Skip to main content

Table 3 Patient-specific model parameters

From: How mathematical modeling could contribute to the quantification of metastatic tumor burden under therapy: insights in immunotherapeutic treatment of non-small cell lung cancer

  Patient KE-01 KE-02 KE-03  
Parameter Explanation     Origin
K Environmental carrying capacity [cells] 1012 1012 1012 fixed, [26]
a Growth rate [1/day] 7.284·10−3 6.877·10−3 6.984·10−3 fitted
   (1.041·10−3) (3.734·10−3) (0.611·10−3)  
m Colonization coefficient [1/cell 1/day] 1.635·10−7 1.984·10−7 2.738·10−7 fitted
   (0.157·10−7) (3.816·10−7) (0.490·10−7)  
α Fractal dimension of tumor cells able to metastasize [-] 2/3 2/3 2/3 fixed, [55]
  Chemotherapeutic drug in use CisPT/Pemet. (1L) - CisPT/Pemet. (1L) Data
μ0 Initial chemotherapy efficiency [-] 0.237 (1.000) - 0.081 (0.917) fitted
μ Refractory effect under chemotherapy application [-] 0.132 (1.000) - 0.132 (1.321) fitted
  Immunotherapeutic drug in use Pembr. (2L) Nivol. (1L) Pembr. (2L) Data
χ Immunotherapeutic effect under application [1/day] 0.067 (0.096) 0.499 (0.078) 0.088 (0.011) fitted
\(c_{i}^{50}\) Drug concentration of immunotherapeutic drug 1.012·1016 1.010·1016 1.009·1016 fitted
  for half-maximal response [molecules per volume] (0.142·1016) (0.089·1016) (0.020·1016)  
\(c_{i}^{st}\) Drug concentration of immunotherapeutic drug 1.41·1018 2.77·1018 1.41·1018 estimated,
  in serum steady state [molecules per volume]     cf. Eq. (10)
T Age of primary tumor at diagnosis [d] 407.1 272.2 336.5 estimated,
      cf. Eq. (3)
TVDT Tumor volume doubling time at diagnosis [d] 91.6 25.9 43.7 estimated,
      cf. Eq. (4)
  1. CisPT/Pemet. = Combination therapy of Cisplatinum and Pemetrexed. Pembr. = Pembrolizumab. Nivol. = Nivolumab. (1L) = First-line therapy. (2L) = Second-line therapy. The values in brackets indicate the corresponding standard errors